摘要
目的:观察化瘀散结灌肠液对子宫内膜异位症(EMT)盆腔痛模型大鼠核因子κB通路、炎症介质及氧化应激因子的影响,探讨化瘀散结灌肠液治疗EMT盆腔痛的机制。方法:40只雌性SD大鼠,按随机数字表法选取6只为假手术组,其余大鼠通过自体子宫内膜移植法联合雌激素加缩宫素注射建立EMT盆腔痛大鼠模型,选取30只造模成功的大鼠按随机数字表法分为模型组、阳性对照组及化瘀散结灌肠液低剂量灌肠组、化瘀散结灌肠液中剂量灌肠组、化瘀散结灌肠液高剂量灌肠组,每组6只。灌肠给药4周后,观察扭体反应,并进行病理观察,检测血清白细胞介素-1β(IL-1β)、肿瘤坏死因子-α(TNF-α)、超氧化物歧化酶(SOD)、丙二醛(MDA)的表达及异位病灶组织核因子κB蛋白的表达水平。结果:与模型组比较,化瘀散结灌肠液低剂量灌肠组、化瘀散结灌肠液中剂量灌肠组、化瘀散结灌肠液高剂量灌肠组大鼠扭体次数显著减少(P<0.05),血清中IL-1β、TNF-α、MDA含量显著降低(P<0.05),SOD含量显著增高(P<0.05),异位病灶组织中核因子κB蛋白表达显著降低(P<0.05)。结论:化瘀散结灌肠液可能通过抑制氧化应激反应抑制核因子κB通路的激活,从而减少炎症介质释放,缓解EMT盆腔痛。
Objective:To observe the effect of Huayu Sanjie enema(HSE)on nuclear factor kappa B(NF-κB)pathway,inflammatory factors,and oxidative stress factors in endometriosis(EMT)rats with pelvic pain,and to explore the mechanism of HSE against pelvic pain in EMT.Methods:Of the 40 female SD rats,6 were randomly selected as the sham operation group with the random number table method.Autologous endometrial transplantation,estrogen,and oxytocin injection were employed to induce EMT with pelvic pain.Then 30 model rats were selected and randomized into model group,positive control group,and low-dose,medium-dose,and high-dose HSE groups,with 6 rats in each group.After 4 weeks of enema administration,the writhing response and pathological changes were observed.The expression of serum interleukin-1β(IL-1β),tumor necrosis factor-α(TNF-α),malondialdehyde(MDA),and superoxide dismutase(SOD)and the expression of NF-κB protein in ectopic lesion tissue were detected.Results:Compared with the model group,low-dose,medium-dose,and high-dose HSE decreased the writhing times(P<0.05)and serum levels of IL-1β,TNF-α,and MDA(P<0.05),raised SOD content(P<0.05),and lowered NF-κB protein expression in ectopic lesion(P<0.05).Conclusion:HSE may inhibit the activation of NF-κB pathway by suppressing oxidative stress,thereby reducing the release of inflammatory factors and alleviating pelvic pain in EMT.
作者
宗春晓
徐信
刘小丽
谢伟
薛晓鸥
朱玉莹
徐立
ZONG Chunxiao;XU Xin;LIU Xiaoli;XIE Wei;XUE Xiaoou;ZHU Yuying;XU Li(Dongzhimen Hospital,Beijing University of Chinese Medicine,Beijing 100010,China)
出处
《世界中医药》
CAS
2022年第23期3347-3351,共5页
World Chinese Medicine
基金
国家自然科学基金项目(81603430)——金雀黄素对人子宫内膜雌激素受体调节及对子宫内膜病变防治机制研究。